Silence Therapeutics’ (SLN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $75.00 price target on the stock.

A number of other equities research analysts have also weighed in on SLN. Wall Street Zen lowered Silence Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. Chardan Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Silence Therapeutics in a research note on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Silence Therapeutics Stock Up 0.4%

Shares of SLN stock opened at $5.03 on Tuesday. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $20.48. The business’s fifty day simple moving average is $5.54 and its 200-day simple moving average is $4.74.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.27). Silence Therapeutics had a negative return on equity of 67.48% and a negative net margin of 294.20%.The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $8.50 million. As a group, research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. purchased a new stake in shares of Silence Therapeutics in the 4th quarter valued at $113,000. Bank of America Corp DE boosted its holdings in Silence Therapeutics by 48,165.6% in the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock valued at $3,434,000 after purchasing an additional 498,032 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock valued at $4,356,000 after purchasing an additional 165,300 shares during the last quarter. Two Sigma Advisers LP grew its position in Silence Therapeutics by 18.6% during the 4th quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock worth $680,000 after purchasing an additional 15,500 shares during the period. Finally, Woodline Partners LP raised its stake in shares of Silence Therapeutics by 22.6% during the 4th quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock valued at $3,431,000 after buying an additional 91,829 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.